Intravenous

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.…

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African…

Highlights: Independent examiners confirm Phase I study of RECCE® 327 (R327) in 80 human subjects across eight cohorts achieved all primary study endpoints, met international regulatory standards, and demonstrated R327 to be safe and…

<!-- Name:DistributionId Value:8812845 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:2791 -->…

Mistletoe extract has been widely used to support cancer therapy and improve quality of life, but there has been a lack of clinical trials and data to support its use. Researchers at the Johns Hopkins Kimmel Cancer Center completed what is…

<!-- Name:DistributionId Value:8753404 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

Reduces maintenance dose from a 15-minute IV infusion to a 30-second, undiluted IV push every two weeksSafety profile of Trogarzo® IV push similar to that of IV infusionNew method of administration designed to make maintenance dosing…

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments Company Will Host Investor Update Tuesday, October 4th KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc.…

Pune, India, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The global prevalence of primary immunodeficiency is rising, giving impetus to the global intravenous immunoglobulins market. A report is published by Fortune Business Insights, titled…

“We are thrilled to offer the very best in concierge IV drip therapy treatment to the New Orleans community,” says Bracha L. Banayan. …